Please login to the form below

Not currently logged in
Email:
Password:

Lighthouse bolsters its US senior scientific team

Marc Pondel joins the agency as executive medical science director

Lighthouse Medical Communications US, part of the Lucid Group companies, has appointed Marc Pondel as its executive medical science director.

Pondel’s new role will see him guide the Lighthouse medical writing teams as he brings scientific and clinical strategic insight knowledge for the agency’s clients.

Andy Willmer, managing director of Lighthouse, said: “As Lighthouse expands its footprint in the USA we must ensure we build a platform of scientific capability that can continually deliver magical programmes for our clients.

“Dr Pondel brings not only a background of scientific excellence but a rich experience of creative communication approaches, which can truly impact patient outcomes.”

Pondel’s career has seen him serve in various senior-level strategic medical and advisory positions, leading teams in a number of key therapeutic areas.

He said: “The Lighthouse team is superbly capable and I look forward to helping them elevate our work in the dynamic US marketplace.

“Our shared passion for developing great medical communications programmes that help to change behaviour and improve outcomes is truly special.”

19th March 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics